type 2 diabetes

ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
ADA: Sanofi bolsters Soliqua with real-world data showing starting insulin, GLP-1 together helps control blood sugar
Fierce Pharma
ADA
diabetes
Sanofi
Soliqua
type 2 diabetes
Flag link:
Fractyl Seeks to Turn Diabetes On Its Ear with Revita DMR
Fractyl Seeks to Turn Diabetes On Its Ear with Revita DMR
Medical Devices and Diagnostics Industry
Fractyl Labs
diabetes
type 2 diabetes
Revita DMR
devices
Medtech
Flag link:
Sanofi culls pipeline dud, still looking to out-license unwanted later-stage meds
Sanofi culls pipeline dud, still looking to out-license unwanted later-stage meds
Fierce Biotech
Sanofi
Regeneron
efpeglenatide
type 2 diabetes
Flag link:
FDA Revamps Safety Testing for new Type 2 Diabetes Drugs
FDA Revamps Safety Testing for new Type 2 Diabetes Drugs
RAPS.org
FDA
type 2 diabetes
Flag link:
Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients
Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients
Pharmaceutical Business Review
Eli Lilly
Trulicity
FDA
type 2 diabetes
Cardiovascular
Flag link:
Preclinical Data Shows Potential Path to Reverse Type-2 Diabetes and Liver Fibrosis
Preclinical Data Shows Potential Path to Reverse Type-2 Diabetes and Liver Fibrosis
BioSpace
Yale
type 2 diabetes
liver fibrosis
Flag link:
NDMA in Metformin: FDA Finds Low Levels in Only 2 of 10 Tested Products
NDMA in Metformin: FDA Finds Low Levels in Only 2 of 10 Tested Products
RAPS.org
NDMA
metformin
FDA
type 2 diabetes
diabetes
Flag link:
Novo Nordisk joins with UVA in diabetes digital simulation project
Novo Nordisk joins with UVA in diabetes digital simulation project
Pharmaforum
Novo Nordisk
UVA
R&D
type 2 diabetes
Flag link:
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
Jardiance phase 3 exercise ability studies in chronic heart failure fail to meet primary endpoint
Pharmaceutical Business Review
Jardiance
Eli Lilly
Boehringer Ingelheim
type 2 diabetes
chronic heart failure
clinical trials
Flag link:
After Zantac scare, FDA targets generic metformin for carcinogen tests
After Zantac scare, FDA targets generic metformin for carcinogen tests
Fierce Pharma
generics
FDA
type 2 diabetes
metformin
Flag link:
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Hitting the road: AstraZeneca launches tour to highlight link between diabetes and heart failure
Fierce Pharma
AstraZeneca
diabetes
type 2 diabetes
heart failure
Flag link:
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Gene therapy to fend off aging? Buzzy Harvard startup Rejuvenate Bio says it works in mice
Fierce Biotech
gene therapy
age-related disease
type 2 diabetes
obesity
heart failure
kidney failure
Rejuvenate Bio
Flag link:
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Lilly and Boehringer rejig diabetes alliance as Jardiance soars
Pharmaforum
Eli Lilly
Boehringer Ingelheim
Jardiance
diabetes
type 2 diabetes
Flag link:
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Lilly counts on growing markets to boost lagging Taltz, Trulicity
Fierce Pharma
Eli Lilly
Trulicity
Taltz
immunology
type 2 diabetes
Flag link:
J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?
J&J's suffering Invokana scores new kidney disease nod. Can it turn sales around?
Fierce Pharma
JNJ
Invokana
diabetic kidney disease
FDA
type 2 diabetes
Flag link:
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Novo Nordisk wins FDA green light for 'holy grail' diabetes drug Rybelsus
Fierce Pharma
Novo Nordisk
oral semaglutide
FDA
Rybelsus
type 2 diabetes
Flag link:
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Novo, e-therapeutics extend Type 2 diabetes research pact to include new genomics tech
Fierce Biotech
Novo Nordisk
e-therapeutics
drug discovery
type 2 diabetes
Flag link:
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Sanofi ends partnership with Lexicon to develop add-on pill for diabetes
Yahoo/Reuters
Sanofi
Lexicon Pharmaceuticals
type 1 diabetes
type 2 diabetes
diabetes
insulin
Flag link:
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Lilly's Study on Higher Doses of Trulicity Meets Endpoint
Yahoo/Zacks.com
Eli Lilly
clinical trials
type 2 diabetes
Trulicity
Flag link:
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Novo Nordisk’s Victoza gets FDA okay for pediatric use
Pharmaforum
Novo Nordisk
Victoza
type 2 diabetes
pediatric
Flag link:

Pages